|Print Page Close Window|
AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The Company is focused on seeking to develop and commercialize its lead candidate tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in North America as a treatment for renal cell carcinoma. AVEO is leveraging multiple partnerships aimed at developing and commercializing tivozanib in oncology indications outside of North America, and progressing its pipeline of novel therapeutic candidates in cancer, cachexia (wasting syndrome) and Pulmonary Arterial Hypertension (PAH).
06/27/17AVEO Oncology Announces $14M in Aggregate Gross Proceeds from Hercules Credit Facility and At-the-market Stock OfferingsRead More
06/23/17AVEO Oncology Announces Positive CHMP Opinion for Tivozanib as a Treatment of Advanced Renal Cell CarcinomaRead More
06/20/17AVEO Oncology Announces Pivotal Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma Reaches Enrollment TargetRead More
02/13/17 8:30 a.m. ET AVEO Oncology at the 19th Annual BIO CEO & Investor Conference
Corporate PresentationAVEO Oncology Corporate Presentation